Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies, Fluidigm Among Tool Vendors to Get CIRM Grants

NEW YORK (GenomeWeb News) – Life Technologies and Fluidigm were among tool vendors and academic research groups that were awarded funding last week from the California Institute for Regenerative Medicine to support the development of tools and reagents for stem cell research.
Life Technologies said that it would use a grant of around $870,000 from CIRM to develop disease models of Lou Gehrig’s disease and other neurodegenerative conditions from human embryonic stem cells.
The firm said that it received a two-year grant to conduct the research. In addition to the disease models, Life Technologies intends to develop accompanying protocols and reagents for genetically engineered stem cells.
Fluidigm was approved for funding of roughly $750,000 to scale up a microfluidic cell culture system that will identify stem cell culture and differentiation, identify genes and small molecules effecting stem cells self-renewal and differentiation, and identify genes and small molecules involving or effecting reprogramming of differentiated cells.
According to CIRM, funding for Fluidigm’s project will support “chip redesign, a new carrier, and new software to interface with a commercial controller.”
In total, CIRM’s governing board approved more than $19 million in funding for this round of grants.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.